# US 11,078,276 B2 · Anti-CD79 antibodies and their uses > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,078,276 B2 - Document ID: US11078276B2 - Status: Granted - Kind: B2 - Application number: 16/591,617 - Filed: 2019-10-03 - Published: 2020-04-09 - Granted: 2021-08-03 - Earliest claimed: 2018-10-03 - Assignees: Nepenthe Bioscience LLC - Applicants: Nepenthe Bioscience LLC - Inventors: James Larrick; Bo Yu; Andrew Mendelsohn; John C. Cambier - Web page: https://patentgrep.com/patent/US11078276B2 ## CPC - C07K 16/2803: {against the immunoglobulin superfamily} - A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells - A61K 40/31: Chimeric antigen receptors [CAR] - A61K 40/4224: {Molecules with a "CD" designation not provided for elsewhere} - A61P 3/10: for hyperglycaemia, e.g. antidiabetics - A61P 19/02: for joint disorders, e.g. arthritis, arthrosis - A61P 21/00: Drugs for disorders of the muscular or neuromuscular system - A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection - C12N 5/0636: {T lymphocytes} - A61K 2039/505: {comprising antibodies} - C07K 14/7051: {T-cell receptor (TcR)-CD3 complex} - C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered - C07K 2317/622: Single chain antibody (scFv) - C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value - C07K 2319/03: containing a transmembrane segment - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) ## Abstract The present disclosure provides humanized and affinity matured antibodies (mAbs) and fragments thereof that specifically bind to CD79 with high affinity. The anti-CD79 mAbs and fragments thereof can be used to treat antibody-associated conditions, including autoimmune diseases, allergies, transplant rejection, or immune-mediated rejection of a therapeutics optionally in combination with an additional therapeutic agent. Furthermore, the anti-CD79 mAbs and fragments thereof can be used for diagnostic purposes, including to detect CD79 cells in biological samples and to diagnose B-cell associated disorders. ## Claims ### Claim 1 An anti-CD79 antibody comprising a heavy chain with a variable region selected from the group consisting of SEQ ID NOs: 9-17, 24-27, 32-41, 71, 72, and 75-77, a light chain with a variable region selected from the group consisting of SEQ ID NOs: 18-23, 28-31, 42-56, and 73-74. ### Claim 2 (depends on 1) The anti-CD79 antibody of claim 1, wherein the variable region of the heavy chain is selected from the group consisting of SEQ ID NOs: 24-27, 71, 75-77 and the variable region of the light chain is selected from the group consisting of SEQ ID NOs: 28-31. ### Claim 3 (depends on 2) The antibody of claim 2, wherein the variable region of the heavy chain is a SEQ ID NO: 25 and the variable region of the light chain is a SEQ ID NO: 30. ### Claim 4 (depends on 2) The antibody of claim 2, wherein the variable region of the heavy chain is a SEQ ID NO: 75 and the variable region of the light chain is a SEQ ID NO: 30. ### Claim 5 (depends on 2) The antibody of claim 2, wherein the variable region of the heavy chain is a SEQ ID NO: 76 and the variable region of the light chain is a SEQ ID NO: 30. ### Claim 6 (depends on 2) The antibody of claim 2, wherein the variable region of the heavy chain is a SEQ ID NO: 77 and the variable region of the light chain is a SEQ ID NO: 30. ### Claim 7 (depends on 2) The antibody of claim 2, wherein the variable region of the heavy chain is a SEQ ID NO: 25 and the variable region of the light chain is a SEQ ID NO: 28. ### Claim 8 (depends on 2) The antibody of claim 2, wherein the variable region of the heavy chain is a SEQ ID NO: 25 and the variable region of the light chain is a SEQ ID NO: 29. ### Claim 9 (depends on 6) The antibody of claim 6, wherein the variable region of the heavy chain is a SEQ ID NO: 25 and the variable region of the light chain is a SEQ ID NO: 31. ### Claim 10 An anti-CD79 antibody comprising a heavy chain with a variable region chain selected from a group consisting of a SEQ ID NOs: 9-17, and a light chain with a variable region selected from the groups consisting of a SEQ ID NOs: 18-23. ### Claim 11 (depends on 10) The anti-CD79 antibody of claim 10, wherein the variable region of the heavy chain is selected from the group consisting of SEQ ID NOs: 9-11 and the variable region of the light chain is selected from the group consisting of SEQ ID NOs: 18-20. ### Claim 12 (depends on 10) The antibody of claim 10, wherein the variable region of the heavy chain is a SEQ ID NO: 9 and the variable region of the light chain is a SEQ ID NO: 19. ### Claim 13 (depends on 10) The antibody of claim 10, wherein the variable region of the heavy chain is a SEQ ID NO: 10 and the variable region of the light chain is a SEQ ID NO: 19.